HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Rigel Pharmaceuticals (NASDAQ:RIGL) and maintains a $15 price target.
February 22, 2024 | 5:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Rigel Pharmaceuticals with a $15 price target.
The reiteration of a Buy rating and a maintained price target of $15 by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for Rigel Pharmaceuticals. This endorsement likely boosts investor confidence and could lead to a short-term positive impact on RIGL's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100